Linked Life Data

11062810

Source:http://linkedlifedata.com/resource/pubmed/id/11062810

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2000-11-21
pubmed:abstractText
Childhood pneumococcal disease is associated with substantial morbidity and mortality, but total disease burden is more difficult to measure than for invasive disease caused by Haemophilus influenzae type b (Hib). A safe, effective seven-valent conjugate pneumococcal vaccine will be available in Australia by early 2001, and will certainly be indicated for high-risk groups and purchased in the private sector, as was Hib vaccine. The status of this vaccine on the Australian Standard Vaccination Schedule will require more detailed consideration of the burden and serotype distribution of pneumococcal disease in Australian children and the vaccine's likely cost-effectiveness. Postmarketing surveillance will be particularly important.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0025-729X
pubmed:author
pubmed:issnType
Print
pubmed:day
2
pubmed:volume
173 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S54-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Conjugate pneumococcal vaccines for non-indigenous children in Australia.
pubmed:affiliation
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, New Children's Hospital, Sydney, NSW. peterm@nch.edu.au
pubmed:publicationType
Journal Article, Review